Hematology (all articles)
Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma
25 Apr, 2023 | 14:11h | UTC
RCT | Blood donor’s sex does not impact transfusion recipients’ survival
19 Apr, 2023 | 13:20h | UTCEffect of Donor Sex on Recipient Mortality in Transfusion – New England Journal of Medicine (link to abstract – $ for full-text)
News release: Sex of blood donor has no effect on recipient survival – Ottawa Hospital
Commentary on Twitter
Observational data are conflicting about whether donor sex influences mortality among transfusion recipients. In a multicenter trial in Canada involving 8719 patients, mortality was not influenced by blood-donor sex. https://t.co/54GKPXSXES pic.twitter.com/uYw1KT15py
— NEJM (@NEJM) April 12, 2023
Review | Long-term outcomes following CAR T cell therapy: what we know so far
18 Apr, 2023 | 13:12h | UTCLong-term outcomes following CAR T cell therapy: what we know so far – Nature Reviews Clinical Oncology (if the link is paywalled, try this one in PMC)
Commentary on Twitter
In a new Review now live online, Kathryn Cappell & James Kochenderfer discuss 'Long-term outcomes following CAR T cell therapy: what we know so far' https://t.co/w89HksK1Ay #ImmunoOnc #hemeonc #medonc #leusm #lymsm #MMSM pic.twitter.com/1MEKWvXcKu
— NatureRevClinOncol (@NatRevClinOncol) April 14, 2023
Phase 2 RCT | Dersimelagon in erythropoietic protoporphyrias
17 Apr, 2023 | 13:05h | UTCDersimelagon in Erythropoietic Protoporphyrias – News England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, once-daily oral treatment with dersimelagon safely improved tolerance to sun exposure in patients with erythropoietic protoporphyria and X-linked protoporphyria. https://t.co/peZye8R5T7 pic.twitter.com/DO2HmKkM1f
— NEJM (@NEJM) April 12, 2023
SR | Oral direct thrombin inhibitors vs. conventional anticoagulants for the treatment of pulmonary embolism
17 Apr, 2023 | 13:02h | UTC
M-A | Efficacy of postpartum pharmacologic thromboprophylaxis
17 Apr, 2023 | 12:55h | UTC
RCT | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia
17 Apr, 2023 | 12:48h | UTC
Review | Inappropriate prescriptions of direct oral anticoagulants (DOACs) in hospitalized patients
12 Apr, 2023 | 13:14h | UTC
Guideline | First line treatment of newly diagnosed transplant ineligible multiple myeloma
11 Apr, 2023 | 14:22h | UTC
Review | Anticoagulation in patients with liver cirrhosis: friend or foe?
11 Apr, 2023 | 14:17h | UTCAnticoagulation in Patients with Liver Cirrhosis: Friend or Foe? – Digestive Diseases and Sciences
Cohort Study | Antiphospholipid antibodies’ prevalence & link to cardiovascular events
10 Apr, 2023 | 13:59h | UTCNews Release: Antiphospholipid antibodies may increase heart disease risk in healthy people – Michigan Medicine
Guidelines on diagnosis and management of chronic neutropenia in adults and children
10 Apr, 2023 | 13:25h | UTC
Commentary on Twitter
Neutropenia diagnosis & management were previously based on physicians' experience or local practices. To harmonize #hematology treatment, #EHA & @eunet_innochron have published a new #EHAGuideline on #neutropenia in adults & children in @Hemasphere_EHA: https://t.co/ifYEtzNlAv pic.twitter.com/CnKuqG03Up
— European Hematology Association (@EHA_Hematology) April 3, 2023
Hydroxyurea use in youths with sickle cell anemia: underused despite updated 2014 guidelines
5 Apr, 2023 | 13:16h | UTCOriginal Guideline: National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014
Commentary on Twitter
Hydroxyurea prescribing in youths with sickle cell anemia insured by Medicaid modestly after the @nih_nhlbi guidelines recommended hydroxurea in 2014. Increasing hydroxyurea use may require a multifaceted approach. https://t.co/tkY0HiMvkv
— JAMA Network Open (@JAMANetworkOpen) March 24, 2023
RCTs | Fitusiran prophylaxis reduces bleeding in people with hemophilia A or hemophilia B
3 Apr, 2023 | 13:44h | UTCEfficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial – The Lancet (link to abstract – $ for full-text)
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
News Release: Monthly injections of fitusiran reduces bleeds in patients with haemophilia A and B – The Lancet
Position Paper | Prehospital hemorrhage control and treatment by clinicians
27 Mar, 2023 | 13:20h | UTC
Study shows increased bleeding complications in ESKD patients undergoing AF ablation
24 Mar, 2023 | 13:09h | UTCSummary: The study analyzed 347 procedures in 307 patients with end-stage kidney disease (ESKD) undergoing atrial fibrillation (AF) catheter ablation in 12 referral centers in Japan.
Despite a vast majority of patients having subtherapeutic international normalized ratio (INR) values during the peri-procedural period, 35 patients (10%) experienced major complications, with the majority being major bleeding events (19 patients; 5.4%), including 11 cases of cardiac tamponade (3.2%). There were also two peri-procedural deaths (0.6%), both related to bleeding events. A pre-procedural INR value of 2.0 or higher was identified as the only independent predictor of major bleeding.
Current peri-procedural anticoagulation guidelines state that patients undergoing AF ablation should be under therapeutic anticoagulation throughout the peri-procedural period. The findings of this study suggest that these guidelines may not be appropriate for ESKD patients undergoing the procedure, and the role of peri-procedural anticoagulation in this population should be further investigated.
Commentary on Twitter
Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing #afib ablation 👉 despite undertreatment with warfarin, the rate of haemorrhagic complications is high! https://t.co/3W8gEtZYdy#kidney #afib #anticoagulation #ablation #cardiotwitter #europace pic.twitter.com/vI27UeIpRf
— European Society of Cardiology Journals (@ESC_Journals) March 16, 2023
RCT | 4F-PCC fails to reduce blood product consumption and raises thromboembolic events in trauma patients
22 Mar, 2023 | 13:41h | UTCSummary: The PROCOAG Randomized Clinical Trial aimed to investigate the efficacy and safety of 4-factor prothrombin complex concentrate (4F-PCC) in trauma patients at risk of massive transfusion. Conducted in 12 French trauma centers, this double-blind, randomized, placebo-controlled superiority trial involved 324 patients. All patients were treated according to European traumatic hemorrhage guidelines and received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1). The primary outcome measured was 24-hour blood product consumption (efficacy), while arterial or venous thromboembolic events were assessed as a secondary outcome (safety).
The trial revealed no significant difference in 24-hour blood product consumption between the 4F-PCC and placebo groups, with median consumption of 12 units and 11 units, respectively. However, the study identified a statistically significant higher risk of thromboembolic events in the 4F-PCC group, with 35% of patients experiencing at least one event compared to 24% in the placebo group.
In conclusion, the study found no beneficial effect of incorporating 4F-PCC into a ratio-based transfusion strategy for patients with severe trauma at risk of massive transfusion. Furthermore, the higher rate of thromboembolic events in the 4F-PCC group indicated potential harm. The findings do not support the routine use of 4F-PCC in patients experiencing trauma who are at risk for extensive transfusion.
Article: Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Review | Diagnosis and treatment of chronic lymphocytic leukemia
22 Mar, 2023 | 13:39h | UTCDiagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review – JAMA (free for a limited period)
Audio clinical review: Diagnosis and Management of Chronic Lymphocytic Leukemia – JAMA
Review | Gene Therapy for Hemophilia — Opportunities and Risks
21 Mar, 2023 | 13:25h | UTCGene Therapy for Hemophilia—Opportunities and Risks – Deutsches Ärzteblatt International
Cohort Study | COVID-19 outpatients mostly at low risk for VTE, but age, being male, and obesity are risk factors
17 Mar, 2023 | 13:11h | UTCSummary: The article discusses a cohort study that aimed to assess the risk of venous thromboembolism (VTE) among outpatients with COVID-19 and identify independent predictors of VTE.
The study used data from two integrated healthcare delivery systems in California and included 398.530 nonhospitalized adults aged 18 years or older with COVID-19 diagnosed between January 1, 2020, and January 31, 2021, with follow-up through February 28, 2021.
The results showed that the overall risk of VTE among outpatients with COVID-19 is low, but higher in the first 30 days after diagnosis. Factors associated with a higher risk of VTE in COVID-19 outpatients included:
- Age 55 years or older.
- Being male.
- history of VTE or thrombophilia.
- Body mass index greater than or equal to 30.0.
The study’s results could inform future randomized trials to explore targeted VTE preventive strategies and more intensive short-term surveillance for patients with COVID-19 who are at a higher risk of developing VTE.
Commentary: Venous blood clots rare among COVID-19 outpatients, study finds – CIDRAP
Commentary on Twitter
The rate of VTE was low in outpatients with #COVID19 in the first 30 days, and even lower >30 days. Factors associated with a higher risk of VTE in included age ≥55, male, prior VTE/thrombophilia, and BMI ≥30. https://t.co/3hwfDW88k4
— JAMA Network Open (@JAMANetworkOpen) March 13, 2023
RCT | Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma
16 Mar, 2023 | 13:07h | UTCOriginal Study: Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
Primary myelofibrosis | 2023 update on diagnosis, risk-stratification, and management
16 Mar, 2023 | 12:57h | UTC
Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders
14 Mar, 2023 | 13:27h | UTC
ISCCM Consensus Statement | Prevention of venous thromboembolism in the critical care unit
13 Mar, 2023 | 14:53h | UTC
DNA sequencing may identify an increased risk of relapse in adults with AML prior to hematopoietic cell transplantation
13 Mar, 2023 | 14:47h | UTCDNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant – JAMA (free for a limited period)
Commentary on Twitter
Among patients w AML in first remission prior to allogeneic hematopoietic cell transplant, the persistence of residual variants in the blood at an allele fraction ≥0.01% was assoc'd w increased relapse & worse survival vs those w/o these variants. https://t.co/KCnaQ1NRXJ
— JAMA (@JAMA_current) March 11, 2023